Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry

This AI model shows promise for reducing unnecessary IHC use in difficult prostate biopsy cases while maintaining diagnostic safety. Its integration into clinical workflows could streamline decision-making in prostate pathology and alleviate resource burdens.